Back to search

Peptide record

TPDB10730

A12L/A20L/A23L Antibacterial Anticancer Antifungal Hemolysis Toxicity standard

26 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB10730

Peptide_Name

A12L/A20L/A23L

Activity

Antibacterial Anticancer Antifungal Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab Antifungipept CAFPdb dbAMP HemoPI Hemolytic2 PD_Hemolysis

Sequence_Type

standard

Has_Modification No

Description A 26-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, ACP740 _ACP240, and other sources, with an available 3D structural model.

Sequence

KWKSFLKTFKSLKKTVLHTLLKLISS

FASTA

>TPDB10730|Antibacterial;Anticancer;Antifungal;Hemolysis;Toxicity|length=26
KWKSFLKTFKSLKKTVLHTLLKLISS

Formula C148H248N36O34

Absent Amino Acids ARNDCEQGMPY

Common Amino Acids K

Mass 3075.82

PI 11.29

Basic Residues 8

Acidic Residues 0

Hydrophobic Residues 11

Net Charge +7

Boman Index 1.12

Hydrophobicity 0.015

Aliphatic Index 116.15

Half Life

Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 5500

Absorbance 280nm 178.81

Polar Residues 7

number

Amino Acid Distribution

A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 1 I: 1 L: 6 K: 7 M: 0 F: 2 P: 0 S: 4 T: 3 W: 1 Y: 0 V: 1

Length

Formula

C148H248N36O34

Mass

3075.82

11.29

Net Charge

Boman Index

1.12

Hydrophobicity

0.015

C_terminal_Modification

Free

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

PeptideV13K

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=9.2 µMo/L

Detail Source Activity Anticancer

Activity Measurement 9.2 µM

Target

Cancer Type Lung Cancer

Cell Line A-549

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 36-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=7.2 µMo/L

Detail Source Activity Anticancer

Activity Measurement 7.2 µM

Target

Cancer Type Skin Cancer

Cell Line A-375

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 36-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=5.7 µMo/L

Detail Source Activity Anticancer

Activity Measurement 5.7 µM

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/MTS assay

Testing Time 36-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=3.5 µMo/L

Detail Source Activity Anticancer

Activity Measurement 3.5 µM

Target

Cancer Type Colorectal Cancer

Cell Line SW-1116

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 36-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=5.5 µMo/L

Detail Source Activity Anticancer

Activity Measurement 5.5 µM

Target

Cancer Type Rhabdomyosarcoma Cancer

Cell Line RD

Tissue Affected Muscle

Assay & Model

Assay MTT/MTS assay

Testing Time 36-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Evidence 6 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=2.7 µMo/L

Detail Source Activity Anticancer

Activity Measurement 2.7 µM

Target

Cancer Type Lung Cancer

Cell Line H-1299

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 36-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Evidence 7 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=4.6 µMo/L

Detail Source Activity Anticancer

Activity Measurement 4.6 µM

Target

Cancer Type Skin Cancer

Cell Line B-16

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 36-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Evidence 8 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50=2.2 µMo/L

Detail Source Activity Anticancer

Activity Measurement 2.2 µM

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 36-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Evidence 9 Activity

Activity

Activity Endpoint 5% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 2.6±0.01 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

5% Hemolysis | 2.6±0.01 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework. | Mol Cancer Ther | 2011

Evidence 10 Hemolysis

Source & Reference

source HemoPI PD_Hemolysis

Database Source PD_Hemolysis